The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Open accessAbstract
Objective: To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. Methods: We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Results: The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional). Conclusion: This clinical practice guideline is intended to serve as a tool to support clinician and patient decision‐making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision‐making process based on patients’ values, goals, preferences, and comorbidities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The updated 2021 guidelines further restrict the use of methotrexate in patients with suspected NAFLD to those with normal liver tests without advanced hepatic fibrosis (stage 3 or 4), detected by noninvasive testing.195”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Self-citationSingh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Self-citationChung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Self-citationSammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E. B., Lockshin, M. D., Marder, W., Guyatt, G., Branch, D. W., Buyon, J., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41191 · Cited by 790
Self-citationDose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604 · cited 1×
“…frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases (62– 65).”
BackgroundPopulation‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Moreland, L. W., O'Dell, J. R., Paulus, H. E., Curtis, J. R., Bathon, J. M., St.Clair, E. W., Bridges, S. L., Zhang, J., McVie, T., Howard, G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34498 · Cited by 389
Self-citationTherapies for Active Rheumatoid Arthritis after Methotrexate Failure
O'Dell, J. R., Mikuls, T. R., Taylor, T. H., Ahluwalia, V., Brophy, M., Warren, S. R., Lew, R. A., Cannella, A. C., Kunkel, G., Phibbs, C. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303006 · Cited by 382
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Strand, V., Balsa, A., Al-Saleh, J., Barile-Fabris, L., Horiuchi, T., Takeuchi, T., Lula, S., Hawes, C., Kola, B., & Marshall, L. (2017) · BioDrugs · doi:10.1007/s40259-017-0231-8 · Cited by 353
Dixon, W. G., Abrahamowicz, M., Beauchamp, M.-E., Ray, D. W., Bernatsky, S., Suissa, S., & Sylvestre, M.-P. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200702 · Cited by 339
Visser, K., & van der Heijde, D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092668 · Cited by 328
Sammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E. B., Lockshin, M. D., Marder, W., Guyatt, G., Branch, D. W., Buyon, J., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24130 · Cited by 323
Self-citationTrial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Rubbert-Roth, A., Enejosa, J., Pangan, A. L., Haraoui, B., Rischmueller, M., Khan, N., Zhang, Y., Martin, N., & Xavier, R. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008250 · Cited by 298
England, B. R., Tiong, B. K., Bergman, M. J., Curtis, J. R., Kazi, S., Mikuls, T. R., O'Dell, J. R., Ranganath, V. K., Limanni, A., Suter, L. G., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.24042 · Cited by 287
Self-citationRoubille, C., & Haraoui, B. P. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.09.005 · Cited by 285
Mycobacterial diseases and antitumour necrosis factor therapy in USA
Winthrop, K., Baxter, R., Liu, L., Varley, C., Curtis, Jr., Baddley, J., McFarland, B., Austin, D., Radcliffe, L., Suhler, E., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200690 · Cited by 274
del Rincón, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M., & Escalante, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38210 · Cited by 264
van Vollenhoven, R., Takeuchi, T., Pangan, A. L., Friedman, A., Mohamed, M. F., Chen, S., Rischmueller, M., Blanco, R., Xavier, R. M., & Strand, V. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41384 · Cited by 230
van Vollenhoven, R. F., Geborek, P., Forslind, K., Albertsson, K., Ernestam, S., Petersson, I. F., Chatzidionysiou, K., & Bratt, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60027-0 · Cited by 228
Buchbinder, R., Barber, M., Heuzenroeder, L., Wluka, A. E., Giles, G., Hall, S., Harkness, A., Lewis, D., Littlejohn, G., Miller, M. H., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23716 · Cited by 217
Burgers, L. E., Raza, K., & van der Helm - van Mil, A. H. (2019) · RMD Open · doi:10.1136/rmdopen-2018-000870 · Cited by 213
Schiff, M. H., Jaffe, J. S., & Freundlich, B. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205228 · Cited by 211
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207628 · Cited by 194
Detert, J., Bastian, H., Listing, J., Weiß, A., Wassenberg, S., Liebhaber, A., Rockwitz, K., Alten, R., Krüger, K., Rau, R., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201612 · Cited by 190
Mercer, L. K., Askling, J., Raaschou, P., Dixon, W. G., Dreyer, L., Hetland, M. L., Strangfeld, A., Zink, A., Mariette, X., Finckh, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209285 · Cited by 188
Goodman, S. M., Springer, B., Guyatt, G., Abdel, M. P., Dasa, V., George, M., Gewurz‐Singer, O., Giles, J. T., Johnson, B., Lee, S., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23274 · Cited by 188
Self-citationLacaille, D., Guh, D. P., Abrahamowicz, M., Anis, A. H., & Esdaile, J. M. (2008) · Arthritis Care & Research · doi:10.1002/art.23913 · Cited by 187
Katchamart, W., Trudeau, J., Phumethum, V, & Bombardier, C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099861 · Cited by 177
Increased risk of mycobacterial infections associated with anti-rheumatic medications
Brode, S. K., Jamieson, F. B., Ng, R., Campitelli, M. A., Kwong, J. C., Paterson, J. M., Li, P., Marchand-Austin, A., Bombardier, C., & Marras, T. K. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206470 · Cited by 167
Goodman, S. M., Springer, B. D., Guyatt, G. H., Abdel, M. P., Dasa, V., George, M., Gewurz‐Singer, O., Giles, J. T., JOHNSON, B. K., Lee, S. C., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40149 · Cited by 155
Self-citationEmery, P. E., Bingham, C. O., Burmester, G. R., Bykerk, V. P., Furst, D. E., Xavier Mariette, A., van der Heijde, D. M. F. M., van Vollenhoven, R., Arendt, C. H., Mountian, I., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209057 · Cited by 109
Self-citationAlbrecht, K., & Zink, A. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1266-4 · Cited by 109
Cantini, F., Niccoli, L., & Goletti, D. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140103 · Cited by 104
Östör, A. J. K., Crisp, A. J., Somerville, M. F., & Scott, D. G. I. (2004) · BMJ · doi:10.1136/bmj.329.7477.1266 · Cited by 90
(2018) · Clinical Liver Disease · doi:10.1002/cld.722 · Cited by 87
George, M., Baker, J. F., Winthrop, K. L., Alemao, E., Chen, L., Connolly, S., Hsu, J. Y., Simon, T. A., Wu, Q., Xie, F., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2217 · Cited by 87
Self-citationPulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab
Schoe, A., van der Laan‐Baalbergen, N., Huizinga, T. W. J., Breedveld, F. C., & van Laar, J. M. (2006) · Arthritis Care & Research · doi:10.1002/art.21716 · Cited by 81
A Review of Methotrexate‐Induced Accelerated Nodulosis
Patatanian, E., & Thompson, D. F. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.13.1157.33525 · Cited by 80
Özen, G., Pedro, S., England, B. R., Mehta, B. Y., Wolfe, F., & Michaud, K. D. (2019) · ACR Open Rheumatology · doi:10.1002/acr2.11064 · Cited by 78
Self-citationAssociation Between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection
Liu, V. X., Winthrop, K. L., Lu, Y., Sharifi, H., Nasiri, H., & Ruoss, S. J. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201804-245oc · Cited by 71
Alexander, P. E., Gionfriddo, M. R., Li, S., Bero, L. A., Stoltzfus, R. J., Neumann, I., Brito, J. P., Djulbegović, B., Montori, V. M., Norris, S. L., et al. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.09.006 · Cited by 63
Liao, T., Lin, C.-F., Chen, Y., Liu, H., & Chen, D. (2016) · Scientific Reports · doi:10.1038/srep29443 · Cited by 54
Bijlsma, J. W. J., & Buttgereit, F. (2016) · Rheumatology · doi:10.1093/rheumatology/kew344 · Cited by 47
Sauer, B. C., Teng, C., Tang, D. H., Leng, J., Curtis, J. R., Mikuls, T. R., Harrison, D. J., & Cannon, G. W. (2016) · Arthritis Care & Research · doi:10.1002/acr.22944 · Cited by 44
Fraenkel, L., Miller, A. S., Clayton, K., Crow‐Hercher, R., Hazel, S., Johnson, B., Rott, L. M., White, W., Wiedmeyer, C., Montori, V. M., et al. (2015) · Arthritis Care & Research · doi:10.1002/acr.22758 · Cited by 42
Self-citationScott, I. C., Ibrahim, F., Panayi, G. S., Cope, A. P., Garrood, T., Vincent, A., Scott, D. L., & Kirkham, B. W. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.12.006 · Cited by 39
Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment
Taki, H., Kawagishi, Y., Shinoda, K., et al. (2009) · Rheumatology International · doi:10.1007/s00296-009-0931-6 · Cited by 33
Erhardt, D. P., Cannon, G. W., Teng, C., Mikuls, T. R., Curtis, J. R., & Sauer, B. C. (2018) · Arthritis Care & Research · doi:10.1002/acr.23759 · Cited by 30
Research works printed but not linked: 13
- Curtis JR, Real‐world outcomes associated with triple therapy versus tumor necrosis factor inhibitor/methotrexate therapy, Arthritis Care Res (Hoboken)
- Pfizer.Pfizer shares co‐primary endpoint results from post‐marketing required safety study of Xeljanz (Tofacitinib) in subjects with rheumatoid arthritis (RA). URL:https://investors.pfizer.com/investor-news/press-release-details/2021/Pfizer-Shares-Co-Primary-Endpoint-Results-from-Post-Marketing-Required-Safety-Study-of-XELJANZ-tofacitinib-in-Subjects-with-Rheumatoid-Arthritis-RA/default.aspx.
- 10.1136/annrheumdis-2013-204882 · doi:10.1136/annrheumdis-2013-204882
- 10.7326/M16-0713 · doi:10.7326/m16-0713
- 10.1136/annrheumdis-2018-213731 · doi:10.1136/annrheumdis-2018-213731
- 10.1007/s00296-017-3749-7 · doi:10.1007/s00296-017-3749-7
- 10.1002/art.39626 · doi:10.1002/art.39626
- 10.1136/bmj.h1389 · doi:10.1136/bmj.h1389
- 10.1136/annrheumdis-2014-205726 · doi:10.1136/annrheumdis-2014-205726
- 10.1002/art.40196 · doi:10.1002/art.40196
- 10.7326/0003-4819-127-5-199709010-00003 · doi:10.7326/0003-4819-127-5-199709010-00003
- 10.1002/1529-0131(199807)41:7<1327::AID-ART30>3.0.CO;2-T · doi:10.1002/1529-0131(199807)41:7<1327::aid-art30>3.0.co;2-t
- 10.1007/s00296-010-1525-z · DOI
Cited by
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Management of Rheumatoid Arthritis: An Overview
Radu, A.-F., & Bungau, S. G. (2021) · Cells · doi:10.3390/cells10112857 · Cited by 1,089
Black, R. J., Cross, M., Haile, L. M., Culbreth, G. T., Steinmetz, J. D., Hagins, H., Kopec, J. A., Brooks, P. M., Woolf, A. D., Ong, K. L., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00211-4 · Cited by 674
Self-citationEnergy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Metadata
- Authors
- Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al‐Gibbawi, M., Baker, J. F., Barbour, K. E., Barton, J. L., Cappelli, L., Chamseddine, F., George, M., Johnson, S. R., Kahale, L., Karam, B. S., Khamis, A. M., Navarro-Millán, I., Mirza, R., Schwab, P., Singh, N., Turgunbaev, M., Turner, A. S., Yaacoub, S., & Akl, E. A.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2021-06-08
- Volume
- 73
- Issue
- 7
- Pages
- 924-939
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W3171954900
- Cited by
- 1,341
- References
- 55
- FWCI
- 134.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.